Resolution to Approve the Prothena Business Demerger Passed at Elan EGM

DUBLIN--()--Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary General Meeting (EGM) held earlier today, the sole ordinary resolution to approve the demerger of the Prothena Business was duly passed. The full text of the resolution was included in the notice of the EGM dated November 12, 2012 which is available on the Company’s website. The details of the votes lodged by proxy are also available on www.elan.com

About Elan

Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.

###

Contacts

Investor Relations:
Chris Burns
Ph: 1-800-252-3526
or
David Marshall
Ph: + 353-1-709-4444
or
Media Relations:
Emer Reynolds
Ph: + 353-1-709-4022
or
Jonathan Birt
Ph: + 44-751-559-7858

Sharing

Contacts

Investor Relations:
Chris Burns
Ph: 1-800-252-3526
or
David Marshall
Ph: + 353-1-709-4444
or
Media Relations:
Emer Reynolds
Ph: + 353-1-709-4022
or
Jonathan Birt
Ph: + 44-751-559-7858